
    
      This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability,
      PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.

      The study schedule includes screening visit (28 days prior to accept the investigational
      medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of
      treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early
      withdrawal).
    
  